The intraperitoneal injection of 2.17-mAlb at high-dose (100 μg/mouse, daily) resulted in weight gain, hyperphagia, increased adiposity, hyperleptinemia, and hyperinsulinemia indicating efficient blockade of leptin signaling in CNS. The gene discussed is LEP; the disease is hyperinsulinism.